Brainstorm Cell Therapeutics Inc. (BCLI) News

Brainstorm Cell Therapeutics Inc. (BCLI): $2.28

0.20 (+9.62%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add BCLI to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#128 of 334

in industry

Filter BCLI News Items

BCLI News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

BCLI News Highlights

  • BCLI's 30 day story count now stands at 4.
  • Over the past 19 days, the trend for BCLI's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about BCLI are STEM, DRUG and PATH.

Latest BCLI News From Around the Web

Below are the latest news stories about BRAINSTORM CELL THERAPEUTICS INC that investors may wish to consider to help them evaluate BCLI as an investment opportunity.

BrainStorm Granted Patents for Allogeneic Exosome Platform-Product in Neurological Disorder Treatments

Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today provided an update on the grant and allowance of three patent applications for NurOwn® and NurOwn-Exosomes.

Yahoo | December 26, 2023

BrainStorm Issues 2023 Letter to Shareholders

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today issued a Letter to shareholders.

Yahoo | December 20, 2023

BCLI: FDA Meeting Provides Clear Path for Planned Phase 3b Trial of NurOwn

By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Clear Path Forward for Phase 3b Trial of NurOwn On December 7, 2023, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) announced the company attended a meeting with the U.S. Food and Drug Administration (FDA) regarding the planned Phase 3b trial for NurOwn in amyotrophic lateral sclerosis (ALS). The company is going

Yahoo | December 8, 2023

BrainStorm Cell Therapeutics Announces Outcome of FDA Meeting on NurOwn® in ALS

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the completion of a productive meeting with the U.S. Food and Drug Administration (FDA) to discuss NurOwn®, its investigational treatment for amyotrophic lateral sclerosis (ALS).

Yahoo | December 7, 2023

BrainStorm Cell Therapeutics Announces In-Person Meeting with the FDA to Discuss Confirmatory Phase 3 Trial for NurOwn® in ALS

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the US Food & Drug Administration (US FDA) has granted the company a meeting to discuss the regulatory path forward for NurOwn® in amyotrophic lateral sclerosis (ALS). The meeting is scheduled to take place on December 6, 2023. Brainstorm will discuss plans for a Special Protocol Assessment (SPA) with the FDA to agree on the overall protocol d

Yahoo | November 20, 2023

BrainStorm Cell Therapeutics to Present at 6th Annual ALS Research Symposia

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced a podium presentation and panel discussion at the 6th Annual ALS Research Symposium hosted by ALS ONE. The presentation will feature new analyses from the NurOwn placebo-controlled Phase 3 amyotrophic lateral sclerosis (ALS) trial that highlight the biological effect of NurOwn through CSF biomarker data. The presentation, titled, "NurOwn for ALS: Biomarker e

Yahoo | November 17, 2023

BCLI: Phase 3b Trial Details to be Discussed with FDA…

By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Meeting with the FDA to Discuss Development Plan for NurOwn® in ALS On October 18, 2023, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) announced that the U.S. Food and Drug Administration (FDA) has invited the company to request an expedited meeting to discuss the path forward for NurOwn® as a treatment for

Yahoo | November 16, 2023

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q3 2023 Earnings Call Transcript

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Greetings, and welcome to the BrainStorm Cell Therapeutics Third Quarter 2023 Earnings Call. At this time, participants are in a listen-only mode. As a reminder, this call is being recorded. And I would now like to introduce your host for today’s […]

Yahoo | November 15, 2023

Q3 2023 Brainstorm Cell Therapeutics Inc Earnings Call

Q3 2023 Brainstorm Cell Therapeutics Inc Earnings Call

Yahoo | November 15, 2023

BrainStorm Cell Therapeutics Announces Third quarter 2023 Financial Results and Provides Corporate Update

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Yahoo | November 14, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!